Doctors are using new technologies to help boost organ transplant surgeries in the US that are now at a record high. » Read More
Gleevec, the daily pill that turned a killer type of leukemia into a manageable disease, may also help slow diabetes, reports NBC News.
L'Oreal is making human skin in the lab to test products and reduce animal testing. Coming soon: 3-D printed skin for tissue engineering.
IBM's A.I. star joins Viome, a biotech start-up that tracks a person's microbiome ecosystem with tech born out of Los Alamos National Lab.
The high cost of health care in the US is nothing compared to the markup on some prescription medicines. We reveal the most expensive drugs.
CNBC's Meg Tirrell takes a look at the potential role artificial intelligence will play in monitoring patient health.
The route to deflazacort's new, higher price is a complicated one.
Alzheimer’s has lagged other health issues when it comes to advocacy. That’s changing, as Alzheimer’s groups push the funding fight.
A project to make synthetic human DNA is in the early stages, but could be within humans to fight disease in less than five years.
For the deaf and hard of hearing, there’s a promising new world of technological innovation.
See how treating musculoskeletal conditions more effectively can benefit everyone in the workplace.
It may be a decade until an FDA-approved treatment is available to treat Zika. One biotech company has come up with another solution.
If you're a man age 55 to 69, one aspect of your medical care may have just gotten a little more confusing.
Iceland is deciphering the genetic codes of its citizens to learn what factors can cause a form of blood cancer.
Involving patients in determining treatments is leading to faster recoveries, better outcomes, and less absenteeism from the workplace.
CNBC's Meg Tirrell reports on the genetic and genealogical studies happening in Iceland.
CNBC's Meg Tirrell takes a look at why Iceland has become a massive genetic hub.
CNBC's Meg Tirrell provides a look at why the tiny country has become a massive genetic hub.
Diagnosing pain caused by musculoskeletal injuries can be complicated. For Dr. Hollis Potter, the pursuit of pain has been her life’s work.
The track record in drug development for Alzheimer's disease has been terrible: a success rate of less than 1 percent.
CNBC's annual study measures all 50 states on more than 60 different metrics.
The International Paris Air Show is celebrating its 52nd anniversary this year with the big movers and shakers in the aerospace and defense industry all attending the event.
International business and political leaders gather in Dalian, China for the 2017 instalment of the World Economic Forum’s Annual Meeting of the New Champions.
Health and hospital stocks rose after the Senate health bill was unveiled.
Doctors are using new technologies to help boost organ transplant surgeries in the US now at a record high.
Chinese pollution has become such a problem that it has actually become an unexpected moneymaker for some large companies.
The Senate bill leaves many of the ACA's provisions in place, but does so with less generous funding.
Nevada's Dean Heller said that he will not support the Senate's bill in its current form.
A study says Trump's victory was propelled more by racial solidarity than his views on trade or entitlements.
Bill Doyle, executive chairman of Novocure, weighs in on the health-care developments in Washington.
CNBC's Morgan Brennan reports on the FDA approving Portola's blood-thinning drug and the company's stock reaction.
Michael Golway, president and CEO at Advanced Solutions explains how his team of engineers are working toward the goal of 3D printing human organs.